Eyelid basal cell carcinoma(BCC)is the most common eyelid malignant tumor. Although eyelid BCC exhibits a relatively low malignancy and metastatic ability, its incidence is rising annually, and extensive attention has been received from clinicians. Currently, surgery is still the first-line treatment, but surgery for locally advanced eyelid BCC may lead to disfigurement and loss of eye function, so new treatment options are still needed. Studies have shown that the pathogenesis of eyelid BCC is associated with the abnormal expression of multiple signaling pathways, especially the Hedgehog and WNT signaling pathways. Their activation plays an important role in eyelid BCC, and these two pathways can also interact with each other to jointly mediate the development of eyelid BCC. Although targeted inhibitors targeting related signaling pathways have begun to be applied in the clinical treatment of eyelid BCC in recent years, disease recurrence, drug resistance and adverse reactions are still common after medication. Therefore, it is urgent to develop new inhibitors targeting different signaling pathways. Therefore, this paper reviews the recent progress on Hedgehog and WNT signaling pathways in eyelid BCC, aiming to provide important scientific basis for finding key targets for eyelid BCC therapy.